These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

459 related articles for article (PubMed ID: 19402073)

  • 1. Vascular endothelial growth factor-targeted therapy in metastatic renal cell carcinoma.
    Rini BI
    Cancer; 2009 May; 115(10 Suppl):2306-12. PubMed ID: 19402073
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Signaling inhibitors in metastatic renal cell carcinoma.
    Escudier B
    Cancer J; 2008; 14(5):325-9. PubMed ID: 18836338
    [TBL] [Abstract][Full Text] [Related]  

  • 3. VEGF-targeted therapy in renal cell carcinoma: active drugs and active choices.
    Rini BI
    Curr Oncol Rep; 2006 Mar; 8(2):85-9. PubMed ID: 16507216
    [TBL] [Abstract][Full Text] [Related]  

  • 4. von Hippel-Lindau gene status and response to vascular endothelial growth factor targeted therapy for metastatic clear cell renal cell carcinoma.
    Choueiri TK; Vaziri SA; Jaeger E; Elson P; Wood L; Bhalla IP; Small EJ; Weinberg V; Sein N; Simko J; Golshayan AR; Sercia L; Zhou M; Waldman FM; Rini BI; Bukowski RM; Ganapathi R
    J Urol; 2008 Sep; 180(3):860-5; discussion 865-6. PubMed ID: 18635227
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeted therapies in metastatic renal cancer in 2009.
    Bastien L; Culine S; Paule B; Ledbai S; Patard JJ; de la Taille A
    BJU Int; 2009 May; 103(10):1334-42. PubMed ID: 19338565
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Improvement in survival end points of patients with metastatic renal cell carcinoma through sequential targeted therapy.
    Calvo E; Schmidinger M; Heng DY; Grünwald V; Escudier B
    Cancer Treat Rev; 2016 Nov; 50():109-117. PubMed ID: 27664394
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Angiogenesis and renal cell carcinoma].
    Billemont B; Méric JB; Izzedine H; Taillade L; Sultan-Amar V; Rixe O
    Bull Cancer; 2007 Jul; 94 Spec No():S232-40. PubMed ID: 17846009
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targeted therapy for metastatic renal cell carcinoma.
    Motzer RJ; Bukowski RM
    J Clin Oncol; 2006 Dec; 24(35):5601-8. PubMed ID: 17158546
    [TBL] [Abstract][Full Text] [Related]  

  • 9. New treatment approaches in metastatic renal cell carcinoma.
    Mancuso A; Sternberg CN
    Curr Opin Urol; 2006 Sep; 16(5):337-41. PubMed ID: 16905978
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Novelties in the treatment for advanced renal-cell cancer].
    Maráz A
    Orv Hetil; 2011 Apr; 152(17):655-62. PubMed ID: 21464023
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [The role of angiogenesis in renal carcinoma].
    Bussolati B; Satolli MA; Camussi G
    G Ital Nefrol; 2008; 25(3):297-305. PubMed ID: 18473301
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Progress in the management of advanced renal cell carcinoma (RCC).
    Tong TQ; Rohde D; Peter S
    Aktuelle Urol; 2010 Jan; 41 Suppl 1():S57-60. PubMed ID: 20094957
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial.
    Rini BI; Escudier B; Tomczak P; Kaprin A; Szczylik C; Hutson TE; Michaelson MD; Gorbunova VA; Gore ME; Rusakov IG; Negrier S; Ou YC; Castellano D; Lim HY; Uemura H; Tarazi J; Cella D; Chen C; Rosbrook B; Kim S; Motzer RJ
    Lancet; 2011 Dec; 378(9807):1931-9. PubMed ID: 22056247
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Molecular biology of renal cell carcinoma.
    Mellado B; Gascón P
    Clin Transl Oncol; 2006 Oct; 8(10):706-10. PubMed ID: 17074668
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sunitinib, sorafenib and mTOR inhibitors in renal cancer.
    Radulovic S; Bjelogrlic SK
    J BUON; 2007 Sep; 12 Suppl 1():S151-62. PubMed ID: 17935273
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Metastatic sarcomatoid renal cell carcinoma treated with vascular endothelial growth factor-targeted therapy.
    Golshayan AR; George S; Heng DY; Elson P; Wood LS; Mekhail TM; Garcia JA; Aydin H; Zhou M; Bukowski RM; Rini BI
    J Clin Oncol; 2009 Jan; 27(2):235-41. PubMed ID: 19064974
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeted Therapy for Metastatic Renal Cell Carcinoma.
    Afriansyah A; Hamid AR; Mochtar CA; Umbas R
    Acta Med Indones; 2016 Oct; 48(4):335-347. PubMed ID: 28143997
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Metastatic renal cell carcinoma treated sequentially with multiple VEGF receptor-targeted inhibitors--a case report.
    Linassier C; Carmier D; Combe P; D'Arcier BF; Bruyere F; Narciso B
    Anticancer Res; 2012 Feb; 32(2):697-700. PubMed ID: 22287765
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of four early posttherapy imaging changes (EPTIC; RECIST 1.0, tumor shrinkage, computed tomography tumor density, Choi criteria) in assessing outcome to vascular endothelial growth factor-targeted therapy in patients with advanced renal cell carcinoma.
    Krajewski KM; Guo M; Van den Abbeele AD; Yap J; Ramaiya N; Jagannathan J; Heng DY; Atkins MB; McDermott DF; Schutz FA; Pedrosa I; Choueiri TK
    Eur Urol; 2011 May; 59(5):856-62. PubMed ID: 21306819
    [TBL] [Abstract][Full Text] [Related]  

  • 20. An update on targeted therapy in metastatic renal cell carcinoma.
    Lombardi G; Zustovich F; Donach M; Dalla Palma M; Nicoletto O; Pastorelli D
    Urol Oncol; 2012; 30(3):240-6. PubMed ID: 20456985
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.